ClinicalTrials.gg
CompletedNCT03422653Updated Apr 26, 2022Results posted

A Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus (KALM-1)

A Phase 3 interventional study of CR845 0.5 mcg/kg and Placebo in Uremic Pruritus, sponsored by Cara Therapeutics, Inc.. Completed at 57 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-04-26.

Sponsored by Cara Therapeutics, Inc. (part of Tvardi Therapeutics, Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
378
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 19 studies testing difelikefalin in Pruritus — 2 open to participants now, 2 under way, none of them phase 3. difelikefalin · Pruritus.

Enrollment
3rd of 19
378 · median 226
Started
2018
with 2 others
Phase 3
9 of 19
none open now
Registered
4th of 19
by date
Lead sponsor
14 of 19
Cara Therapeutics, Inc.

Among the 19 studies testing difelikefalin in Pruritus, this one is the 3rd largest by enrollment, is one of 3 that started in 2018, is one of 9 in phase 3, and was the 4th registered.

Pruritus

491 studies on the registry are indexed under Pruritus; 94 are open to participants now.

Browse Pruritus studies →

Open to participants now

2 of the 19 studies testing difelikefalin in Pruritus are open now, in 7 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About difelikefalin

difelikefalin: first FDA approval 2021 (KORSUVA), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 54 Pruritus studies recruiting now, 22 (41%) set no upper age limit and 24 (44%) stop at 75 or younger; 15 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing difelikefalin in Pruritus, or all of them as a file.
02

Study summary

This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of intravenous (IV) CR845 at a dose of 0.5 mcg/kg administered after each dialysis session. The study includes a 12-week Double-blind Phase and a 52-week Open-label Extension Phase.

Read the detailed description

Double-blind Phase The Double-blind Phase of the study will consist of a Screening Visit, a 7-day Run-in Period, a 12 week Double-blind Treatment Period, and a 2-week Discontinuation Period. Informed consent will be obtained prior to performing any study-specific procedures. The Screening Visit will occur within 7 to 28 days prior to randomization to assess eligibility.

Open-label Extension Phase Patients who received at least 30 doses of study drug (either active or placebo) during the 12-week Double-blind Treatment Period and continue to meet other eligibility criteria will have the option to receive open label CR845 for an additional 52 weeks. The Open-label Extension Phase will be comprised of the Open-label Treatment Period and the Follow-up Period.

The last dose of open-label study drug will be administered at the last dialysis visit on Week 52, or Early Termination. A final safety Follow up Visit will be conducted 7-10 days after the End of Treatment/Early Termination Visit.

03

Conditions studied

  • Uremic Pruritus

Keywords

  • CR845
  • Pruritus
  • Chronic Itch
  • Itch
  • Itching
  • difelikefalin
  • Hemodialysis
  • Uremic Pruritus
  • Dialysis
  • CKD
  • CKD-associated pruritus
  • CKD-aP
  • ESRD (end stage renal disease)
  • KALM
  • Chronic Kidney Disease
  • Kidney failure, chronic
  • Kidney dysfunction
  • Generalized pruritus
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

To be eligible for inclusion into the Double-blind Phase of the study, a patient must meet the following criteria:

  • Has end-stage renal disease (ESRD) and has been on hemodialysis 3 times per week for at least 3 months prior to the start of screening;
  • Has at least 2 single-pool Kt/V measurements ≥1.2, or at least 2 urea reduction ratio measurements ≥65%, or 1 single pool Kt/V measurement ≥1.2 and 1 urea reduction ratio measurement ≥65% on different dialysis days during the 3 months period prior to screening;
  • Prior to randomization:

    • Has completed Worst Itching Intensity NRS worksheets up to 8 days prior to 1st dose;
    • Has a mean baseline Worst Itching Intensity NRS indicative of moderate to severe uremic pruritus.
  • To be eligible for inclusion into the Open-label Extension Phase of the study, each patient will have to fulfill the additional key following criteria at the time of entry into the Open-label Extension Phase:

    • Has received at least 30 doses of the planned 36 doses of study drug during the Double-blind Phase of this study;
    • Continues to meet inclusion criteria.

Key Exclusion Criteria:

A patient will be excluded from the Double-blind Phase of the study if any of the following criteria are met:

  • Known noncompliance with dialysis treatment that in the opinion of the investigator would impede completion or validity of the study;
  • Scheduled to receive a kidney transplant during the study;
  • New or change of treatment received for itch including antihistamines and (oral, IV, or topical) within 14 days prior to screening;
  • Received another drug within 30 days prior to the start of screening or is planning to participate in another clinical study while enrolled in this study;
  • Has pruritus only during the dialysis session (by patient report);
  • Is receiving ongoing ultraviolet B and anticipates receiving such treatment during the study;
  • Participated in a previous clinical study with CR845.
  • A patient will be excluded from the Open-label Extension Phase of the study if any of the additional key following criteria are met at the time of entry into the Open-label Extension Phase:

    • Completed the Double-blind Phase of this study but exhibited adverse events during the course of the Treatment Period that may preclude continued exposure to the study drug;
    • Was noncompliant with protocol procedures during the Double-blind Phase of this study which is indicative of an inability to follow protocol procedures.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
378 participants (actual)

Study arms

  • Active comparator
    CR845 0.5mcg/kg

    IV CR845 0.5 mcg/kg administered after each dialysis session (3 times/week)

    Drug: CR845 0.5 mcg/kg

  • Placebo comparator
    Placebo

    IV Placebo administered after each dialysis session (3 times/week)

    Drug: Placebo

Interventions

  • DrugCR845 0.5 mcg/kg

    Drug page: Difelikefalin

    IV medication delivered three times/week

    Also known as: CR845, Difelikefalin

  • DrugPlacebo

    IV medication delivered three times/week

06

What researchers measure

Primary outcomes

  1. Reduction of Itch Intensity as Assessed by the Percentage of Patients Achieving an Improvement From Baseline ≥3 Points With Respect to the Weekly Mean of the Daily 24-hour Worst Itching Intensity Numerical Rating Scale (NRS) Score at Week 12

    Intensity of itch will be measured using an NRS used to indicate the intensity of the worst itching over the past 24 hours using a 0 to 10 numeric rating scale, where "0" represents "no itching" and "10" represents "worst itching imaginable". LS means estimated percent, odds ratio and P value used a logistic regression model.

    Time frame: Week 12

Secondary outcomes

  1. Improvement in Itch-related Quality of Life as Assessed by the Change From Baseline in 5-D Itch Scale Score at the End of Week 12

    The 5-D Itch Scale is a multidimensional questionnaire which assesses itch-related quality of life over the past 2 weeks. The questions cover five dimensions of itch including the degree, duration of itch/day, direction (improvement/worsening), disability (impact on activities such as work), and body distribution of itch. The 5-D Itch Scale has 5 questions; the total 5-D Itch Scale score ranges from 5 to 25, with higher scores indicating worse responses.

    Time frame: Baseline, Week 12

  2. Improvement in Itch-related Quality of Life as Assessed by the Change From Baseline in Total Skindex-10 Scale Score at the End of Week 12

    The Skindex-10 Scale is a multidimensional questionnaire which assesses itch-related quality of life over the past week. The questions cover 3 domains: disease, mood/emotional distress, and social functioning domain. The Skindex-10 has 10 questions; the total Skindex-10 score ranges from 0 to 60. A lower total score represents better quality of life.

    Time frame: Baseline, Week 12

  3. Reduction of Itch Intensity as Assessed by the Percentage of Patients Achieving an Improvement From Baseline ≥4 Points With Respect to the Weekly Mean of the Daily 24-hour Worst Itching Intensity NRS Score at Week 12

    Intensity of itch will be measured using an NRS used to indicate the intensity of the worst itching over the past 24 hours using a 0 to 10 numeric rating scale, where "0" represents "no itching" and "10" represents "worst itching imaginable". LS means estimated percent, odds ratio and P value used a logistic regression model.

    Time frame: Week 12

07

Results

Posted Apr 26, 2022

Participant flow

Period 1: Double-blind Phase
Participant flow — Period 1: Double-blind Phase
MilestoneDouble-blind CR845 0.5mcg/kgDouble-blind PlaceboOpen-label CR845 0.5 mcg/kg
Started1891890
Completed1621700
Not completed27190
Period 2: Open-label Phase
Participant flow — Period 2: Open-label Phase
MilestoneDouble-blind CR845 0.5mcg/kgDouble-blind PlaceboOpen-label CR845 0.5 mcg/kg
Started00313
Completed00189
Not completed00124

Outcome measures

PrimaryReduction of Itch Intensity as Assessed by the Percentage of Patients Achieving an Improvement From Baseline ≥3 Points With Respect to the Weekly Mean of the Daily 24-hour Worst Itching Intensity Numerical Rating Scale (NRS) Score at Week 12

Intensity of itch will be measured using an NRS used to indicate the intensity of the worst itching over the past 24 hours using a 0 to 10 numeric rating scale, where "0" represents "no itching" and "10" represents "worst itching imaginable". LS means estimated percent, odds ratio and P value used a logistic regression model.

Time frame:
Week 12
Reported as:
Number · percentage of subjects
Reduction of Itch Intensity as Assessed by the Percentage of Patients Achieving an Improvement From Baseline ≥3 Points With Respect to the Weekly Mean of the Daily 24-hour Worst Itching Intensity Numerical Rating Scale (NRS) Score at Week 12
percentage of subjectsCR845 0.5mcg/kgPlacebo
Reduction of Itch Intensity as Assessed by the Percentage of Patients Achieving an Improvement From Baseline ≥3 Points With Respect to the Weekly Mean of the Daily 24-hour Worst Itching Intensity Numerical Rating Scale (NRS) Score at Week 1251.0 (42.9 to 58.9)27.6 (20.2 to 36.6)
Statistical analysis
  • CR845 0.5mcg/kg vs Placebo · Cui, Hung, Wang · p = <0.001 · Odds ratio (or): 2.72 · 95% CI 1.72 to 4.30
SecondaryImprovement in Itch-related Quality of Life as Assessed by the Change From Baseline in 5-D Itch Scale Score at the End of Week 12

The 5-D Itch Scale is a multidimensional questionnaire which assesses itch-related quality of life over the past 2 weeks. The questions cover five dimensions of itch including the degree, duration of itch/day, direction (improvement/worsening), disability (impact on activities such as work), and body distribution of itch. The 5-D Itch Scale has 5 questions; the total 5-D Itch Scale score ranges from 5 to 25, with higher scores indicating worse responses.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · score on a scale
Improvement in Itch-related Quality of Life as Assessed by the Change From Baseline in 5-D Itch Scale Score at the End of Week 12
score on a scaleDouble-blind CR845 0.5mcg/kgDouble-blind Placebo
Improvement in Itch-related Quality of Life as Assessed by the Change From Baseline in 5-D Itch Scale Score at the End of Week 12-5.0 (-5.7 to -4.4)-3.7 (-4.4 to -3.1)
Statistical analysis
  • Double-blind CR845 0.5mcg/kg vs Double-blind Placebo · ANCOVA · p = <0.001 · Mean difference (final values): -1.3 · 95% CI -2.0 to -0.5
SecondaryImprovement in Itch-related Quality of Life as Assessed by the Change From Baseline in Total Skindex-10 Scale Score at the End of Week 12

The Skindex-10 Scale is a multidimensional questionnaire which assesses itch-related quality of life over the past week. The questions cover 3 domains: disease, mood/emotional distress, and social functioning domain. The Skindex-10 has 10 questions; the total Skindex-10 score ranges from 0 to 60. A lower total score represents better quality of life.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · score on a scale
Improvement in Itch-related Quality of Life as Assessed by the Change From Baseline in Total Skindex-10 Scale Score at the End of Week 12
score on a scaleDouble-blind CR845 0.5mcg/kgDouble-blind Placebo
Improvement in Itch-related Quality of Life as Assessed by the Change From Baseline in Total Skindex-10 Scale Score at the End of Week 12-17.2 (-19.6 to -14.7)-12.0 (-14.5 to -9.6)
Statistical analysis
  • Double-blind CR845 0.5mcg/kg vs Double-blind Placebo · ANCOVA · p = <0.001 · Mean difference (final values): -5.1 · 95% CI -8.0 to -2.3
SecondaryReduction of Itch Intensity as Assessed by the Percentage of Patients Achieving an Improvement From Baseline ≥4 Points With Respect to the Weekly Mean of the Daily 24-hour Worst Itching Intensity NRS Score at Week 12

Intensity of itch will be measured using an NRS used to indicate the intensity of the worst itching over the past 24 hours using a 0 to 10 numeric rating scale, where "0" represents "no itching" and "10" represents "worst itching imaginable". LS means estimated percent, odds ratio and P value used a logistic regression model.

Time frame:
Week 12
Reported as:
Number · percentage of subjects
Reduction of Itch Intensity as Assessed by the Percentage of Patients Achieving an Improvement From Baseline ≥4 Points With Respect to the Weekly Mean of the Daily 24-hour Worst Itching Intensity NRS Score at Week 12
percentage of subjectsDouble-blind CR845 0.5mcg/kgDouble-blind Placebo
Reduction of Itch Intensity as Assessed by the Percentage of Patients Achieving an Improvement From Baseline ≥4 Points With Respect to the Weekly Mean of the Daily 24-hour Worst Itching Intensity NRS Score at Week 1238.9 (29.8 to 48.7)18.0 (12.1 to 26.0)
Statistical analysis
  • Double-blind CR845 0.5mcg/kg vs Double-blind Placebo · Cui, Hung, Wang · p = <0.001 · Odds ratio (or): 2.89 · 95% CI 1.75 to 4.76

Adverse events

Collected over The period of adverse event reporting will start after the signing of the informed consent form (ICF) through the study Follow-up Visit or Early Termination Visit (or 7 days after the last dose if no Early Termination Visit was conducted).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Double-blind CR845 0.5mcg/kg2/189 (1.1%)49/189 (25.9%)40/189 (21.2%)
Double-blind Placebo2/188 (1.1%)41/188 (21.8%)30/188 (16%)
Open-label CR845 0.5 mcg/kg22/313 (7%)167/313 (53.4%)205/313 (65.5%)
Most frequent serious events
Showing 10 of 242
Most frequent serious events
EventDouble-blind CR845 0.5mcg/kgDouble-blind PlaceboOpen-label CR845 0.5 mcg/kg
PneumoniaInfections and infestations3/1895/18823/313
Fluid overloadMetabolism and nutrition disorders2/1894/18816/313
HyperkalaemiaMetabolism and nutrition disorders4/1894/18812/313
Cardiac failure congestiveCardiac disorders1/1891/18811/313
Respiratory failureRespiratory, thoracic and mediastinal disorders2/1890/18811/313
SepsisInfections and infestations3/1894/18810/313
Metabolic encephalopathyNervous system disorders1/1892/18810/313
DyspnoeaRespiratory, thoracic and mediastinal disorders1/1891/18810/313
Mental status changesPsychiatric disorders2/1892/1889/313
AstheniaGeneral disorders2/1890/1888/313
Most frequent other events
Showing 10 of 22
Most frequent other events
EventDouble-blind CR845 0.5mcg/kgDouble-blind PlaceboOpen-label CR845 0.5 mcg/kg
DiarrhoeaGastrointestinal disorders18/18910/18861/313
NauseaGastrointestinal disorders7/1899/18854/313
FallInjury, poisoning and procedural complications6/1898/18850/313
HypotensionVascular disorders7/1894/18849/313
VomitingGastrointestinal disorders10/1896/18843/313
CoughRespiratory, thoracic and mediastinal disorders9/1894/18836/313
HeadacheNervous system disorders8/1894/18836/313
DizzinessNervous system disorders13/1893/18835/313
HyperkalaemiaMetabolism and nutrition disorders7/1893/18835/313
Muscle spasmsMusculoskeletal and connective tissue disorders6/1898/18835/313

Baseline characteristics

Age, Continuous
Age, Continuous(years)Double-blind CR845 0.5mcg/kgDouble-blind PlaceboTotal
Mean58.2 ± 11.1656.7 ± 13.8957.5 ± 12.6
Sex: Female, Male
Sex: Female, Male(Participants)Double-blind CR845 0.5mcg/kgDouble-blind PlaceboTotal
Female7770147
Male112119231
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Double-blind CR845 0.5mcg/kgDouble-blind PlaceboTotal
American Indian or Alaska Native6511
Asian6713
Native Hawaiian or Other Pacific Islander246
Black or African American8276158
White9193184
More than one race123
Unknown or Not Reported123
08

Study locations

57 sites
  • Cara Therapeutics Study Site
    Homewood, Alabama 35209, United States
  • Cara Therapeutics Study Site
    Huntsville, Alabama 35805, United States
  • Cara Therapeutics Study Site
    Bakersfield, California 93309-5030, United States
  • Cara Therapeutics Study Site 2
    Beverly Hills, California 90211, United States
  • Cara Therapeutics Study Site
    Beverly Hills, California 90211, United States
  • Cara Therapeutics Study Site
    Chula Vista, California 91910, United States
  • Cara Therapeutics Study Site
    Corona, California 92881, United States
  • Cara Therapeutics Study Site
    Escondido, California 92025, United States
  • Cara Therapeutics Study Site
    Fountain Valley, California 92708, United States
  • Cara Therapeutics
    La Mesa, California 91942, United States
  • Cara Therapeutics Study Site
    Long Beach, California 90807, United States
  • Cara Therapeutics Study Site
    Ontario, California 91762, United States
  • Cara Therapeutics Study Site
    Riverside, California 92505, United States
  • Cara Therapeutics Study Site
    Roseville, California 95661, United States
  • Cara Therapeutics Study Site
    San Diego, California 92111, United States
  • Cara Therapeutics Study Site
    San Dimas, California 91773, United States
  • Cara Therapeutics Study Site
    Tarzana, California 91356, United States
  • Cara Therapeutics Study Site
    Denver, Colorado 80218, United States
  • Cara Therapeutics Study Site
    Bridgeport, Connecticut 06606, United States
  • Cara Therapeutics Study Site
    Hartford, Connecticut 06112, United States
  • Cara Therapeutics Study Site
    Middlebury, Connecticut 06762, United States
  • Cara Therapeutics Study Site 1
    Coral Springs, Florida 33071, United States
  • Cara Therapeutics Study Site
    Hialeah, Florida 33016, United States
  • Cara Therapeutics Study Site
    Miami Gardens, Florida 33169, United States
  • Cara Therapeutics Study Site
    Miami, Florida 33125, United States
  • Cara Therapeutics Study Site
    Tampa, Florida 33614, United States
  • Cara Therapeutics Study Site
    Kalamazoo, Michigan 49007, United States
  • Cara Therapeutics Study Site
    Roseville, Michigan 48066, United States
  • Cara Therapeutics Study Site
    Minneapolis, Minnesota 55404, United States
  • Cara Therapeutics Study Site
    Brookhaven, Mississippi 39601, United States
  • Cara Therapeutics Study Site
    McComb, Mississippi 39648, United States
  • Cara Therapeutics Study Site
    Tupelo, Mississippi 38801, United States
  • Cara Therapeutics Study Site
    Kansas City, Missouri 64111, United States
  • Cara Therapeutics Study Site
    Las Vegas, Nevada 89102, United States
  • Cara Therapeutics Study Site
    Las Vegas, Nevada 89106, United States
  • Cara Therapeutics Study Site
    Eatontown, New Jersey 07724, United States
  • Cara Therapeutics Study Site
    Albuquerque, New Mexico 87109, United States
  • Cara Therapeutics Study Site
    Gallup, New Mexico 87301, United States
  • Cara Therapeutics Study Site
    Bronx, New York 10461, United States
  • Cara Therapeutics Study Site
    Fresh Meadows, New York 11365, United States
  • Cara Therapeutics Study Site
    Great Neck, New York 11021, United States
  • Cara Therapeutics Study Site
    Durham, North Carolina 27704, United States
  • Cara Therapeutics Study Site
    Canton, Ohio 44718, United States
  • Cara Therapeutics Study Site
    Roseburg, Oregon 97471, United States
  • Cara Therapeutics Study Site
    Chattanooga, Tennessee 37408, United States
  • Cara Therapeutics Study Site
    Dallas, Texas 75231, United States
  • Cara Therapeutics Study Site
    Duncanville, Texas 75137, United States
  • Cara Therapeutics Study Site
    Greenville, Texas 75402, United States
  • Cara Therapeutics Study Site
    Houston, Texas 77054, United States
  • Cara Therapeutics Study Site
    Lewisville, Texas 75057, United States
  • Cara Therapeutics Study Site
    McAllen, Texas 78503, United States
  • Cara Therapeutics Study Site
    Mesquite, Texas 75150, United States
  • Cara Therapeutics Study Site
    San Antonio, Texas 78207, United States
  • Cara Therapeutics Study Site
    Waxahachie, Texas 75165, United States
  • Cara Therapeutics Study Site
    Chesapeake, Virginia 23320, United States
  • Cara Therapeutics Study Site
    Hampton, Virginia 23666, United States
  • Cara Therapeutics Study Site
    Wauwatosa, Wisconsin 53226, United States
09

References and documents

Publications

  • Fishbane S, Wen W, Munera C, Lin R, Bagal S, McCafferty K, Menzaghi F, Goncalves J. Safety and Tolerability of Difelikefalin for the Treatment of Moderate to Severe Pruritus in Hemodialysis Patients: Pooled Analysis From the Phase 3 Clinical Trial Program. Kidney Med. 2022 Jun 28;4(8):100513. doi: 10.1016/j.xkme.2022.100513. eCollection 2022 Aug. PubMed 36039153 ↗
  • Topf J, Wooldridge T, McCafferty K, Schomig M, Csiky B, Zwiech R, Wen W, Bhaduri S, Munera C, Lin R, Jebara A, Cirulli J, Menzaghi F. Efficacy of Difelikefalin for the Treatment of Moderate to Severe Pruritus in Hemodialysis Patients: Pooled Analysis of KALM-1 and KALM-2 Phase 3 Studies. Kidney Med. 2022 Jun 28;4(8):100512. doi: 10.1016/j.xkme.2022.100512. eCollection 2022 Aug. PubMed 36016762 ↗
  • Hercz D, Jiang SH, Webster AC. Interventions for itch in people with advanced chronic kidney disease. Cochrane Database Syst Rev. 2020 Dec 7;12(12):CD011393. doi: 10.1002/14651858.CD011393.pub2. PubMed 33283264 ↗
  • Fishbane S, Jamal A, Munera C, Wen W, Menzaghi F; KALM-1 Trial Investigators. A Phase 3 Trial of Difelikefalin in Hemodialysis Patients with Pruritus. N Engl J Med. 2020 Jan 16;382(3):222-232. doi: 10.1056/NEJMoa1912770. Epub 2019 Nov 8. PubMed 31702883 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2018 to primary completion in Apr 2019, 13 months.

Results were first posted in Apr 2022, 3 years after primary completion. A results delay was requested in Jul 2020.

Of 42 industry-sponsored phase 3 interventional studies under Pruritus, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 26. This study's 13 months is below that.

Counting every sponsor, half of 48 studies reached it within 19 months; a quarter within 12 and three quarters within 29.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 25, 2018
First posted
Feb 6, 2018
StartActual
Feb 20, 2018
Primary completionActual
Apr 6, 2019
CompletionActual
Mar 26, 2020
Results delay requested
Jul 14, 2020
Results first posted
Apr 26, 2022
Last update
Apr 26, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 26, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03422653
Responsible party
Sponsor
First posted
Feb 6, 2018
Start date
Feb 20, 2018
Primary completion
Apr 6, 2019
Completion
Mar 26, 2020
Results posted
Apr 26, 2022
Last update
Apr 26, 2022

Study contacts

Frédérique Menzaghi, PhD
study director · Cara Therapeutics

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Difelikefalin

Start the discussion